Latest From Alteogen Inc.
A busy stretch of deal-making across Asia all includes transactions involving Innovent, Alector, Ono, Numab, Alphamab, 3DMed, Healios, Athersys, Laekna, Novartis, Asahi Kasei, SBI Biotech, Glenmark, Hindustan Unilever, Hanlim, Alteogen, Ildong, Evotec, AJU Pharm, Ribomec, Tyligand, Context
Asia Deal Watch: RAPT And Hanmi Partner On CCR4 Antagonist Offering Potential In Multiple Cancer Types
RAPT can earn up to $108m in milestones plus sales royalties under the deal. BerGenBio, Piramal partner on developing AML therapy.
Deal follows 2013 pact between Ambrx and NovoCodex parent Zhejiang Medicine for HER2-positive-directed ADC. Astellas teams with Pandion on pancreatic cancer and Takeda with MD Anderson on CAR NK therapies.
Mylan’s proposal to progress studies for its aflibercept biosimilar has been endorsed by an expert panel in India, which expects availability of such biosimilars to expand access to anti-VEGF therapies.
- Large Molecule
- Drug Delivery
- Therapeutic Areas
- Immune Disorders
- Respiratory, Pulmonary
- South Korea
- Pacific Rim
- Parent & Subsidiaries
- Alteogen Inc.
- Senior Management
Soon Jae Park, PhD, CEO
Moon Hwan Park, SVP, CFO
Hye-Shin Chung, PhD, CTO
Kyeong-Hoon Jeong, PhD, VP, Head R&D
- Contact Info
62 Yuseong-daero 1628, beon-gi
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.